A comprehensive review by Centore et al., was published in 2020 based on the large-scale cancer genome-sequencing studies showed targeted therapies in different cancers based on this complex mutation, for example, ARID1A mutation as a hallmark in the bladder, stomach, and endometrial cancers which targeted by ARID1B selective degrader, EZH2 inhibitors and P13K inhibitors. This evidence concerns the gene ARID1B and cancer.